Daiwa Securities Group’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,372
| Closed | -$99K | – | 1395 |
|
|
2025
Q4 | $99K | Sell |
1,372
-5,403
| -80% | -$349K | ﹤0.01% | 1044 |
|
|
2025
Q3 | $295K | Buy |
6,775
+4,427
| +189% | +$179K | ﹤0.01% | 951 |
|
|
2025
Q2 | $67K | Buy |
2,348
+132
| +6% | +$3.93K | ﹤0.01% | 1028 |
|
|
2025
Q1 | $65K | Sell |
2,216
-66
| -3% | -$2.06K | ﹤0.01% | 995 |
|
|
2024
Q4 | $66K | Buy |
2,282
+175
| +8% | +$7.31K | ﹤0.01% | 1032 |
|
|
2024
Q3 | $97K | Buy |
2,107
+15
| +0.7% | +$651 | ﹤0.01% | 1014 |
|
|
2024
Q2 | $85K | Sell |
2,092
-7,889
| -79% | -$226K | ﹤0.01% | 1040 |
|
|
2024
Q1 | $255K | Sell |
9,981
-556
| -5% | -$8.71K | ﹤0.01% | 948 |
|
|
2023
Q4 | $95K | Buy |
10,537
+3,182
| +43% | +$21.3K | ﹤0.01% | 1019 |
|
|
2023
Q3 | $47K | Hold |
7,355
| – | – | ﹤0.01% | 1067 |
|
|
2023
Q2 | $82K | Buy |
7,355
+272
| +4% | +$3.41K | ﹤0.01% | 1039 |
|
|
2023
Q1 | $109K | Buy |
7,083
+1,348
| +24% | +$29.7K | ﹤0.01% | 984 |
|
|
2022
Q4 | $127K | Buy |
5,735
+955
| +20% | +$14.2K | ﹤0.01% | 973 |
|
|
2022
Q3 | $78K | Buy |
4,780
+4,624
| +2,964% | +$88.5K | ﹤0.01% | 1026 |
|
|
2022
Q2 | $2K | Hold |
156
| – | – | ﹤0.01% | 1253 |
|
|
2022
Q1 | $3K | Hold |
156
| – | – | ﹤0.01% | 1227 |
|
|
2021
Q4 | $4K | Hold |
156
| – | – | ﹤0.01% | 1227 |
|
|
2021
Q3 | $4K | Buy |
156
+85
| +120% | +$1.85K | ﹤0.01% | 1199 |
|
|
2021
Q2 | $2K | Hold |
71
| – | – | ﹤0.01% | 1153 |
|
|
2021
Q1 | $2K | Hold |
71
| – | – | ﹤0.01% | 1159 |
|
|
2020
Q4 | $2K | Buy |
+71
| New | +$2.07K | ﹤0.01% | 1135 |
|
Other funds holding RNAM
Daiwa Securities Group's RNAM Position: Q1 2026 in Review
Daiwa Securities Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,372 shares — an estimated $99K sold.
Daiwa Securities Group first reported a position in RNAM in Q4 2020 and held it in 21 quarters. The position peaked at $295K in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Daiwa Securities Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 1,372 Avidity Biosciences shares in Q1 2026, an estimated $99K.
- Daiwa Securities Group first reported a position in Avidity Biosciences in Q4 2020 and held it in 21 quarters.
- Daiwa Securities Group's Avidity Biosciences position peaked at $295K in Q3 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.